This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-20 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
=== Hollow microneedles === Hollow MNs are designed with a hole at the tip and a hollow capacity that store drugs. Upon MNs insertion, the stored drug is directly injected into the dermis and this effectively facilitates the absorption of either large-molecular or large-dosage drug. Yet, a portion of the drug can leaked or become clogged, and may hinder the overall drug administration. Since the delivery of the drug depends on the flow rate of the microneedle, this type of array could become clogged by excessive swelling or flawed design. This design also increases the likelihood of buckling under the pressure and therefore failing to deliver any drugs.
== Function == Cystinosin functions as a symporter which actively transports protons and cystine, the oxidized cysteine dimer, out of the lysosome. Cystinosin only transports L-CySS while other cystine transporters will work on various amino acids. If cystine builds up in the lysosome it will inhibit the normal functioning of the organelle making the transport function important in the regular functioning of cells. Cystinosin has also been discovered in melanosomes and has been linked to the control and regulation of melanin.
=== Microspheres === Microspheres are hollow, micron-sized carriers often formed via self-assembly of polymeric compounds which are most often used to encapsulate the active drug for delivery. Drug release is often achieved by diffusion through pores in the microsphere structure or by degradation of the microsphere shell. Some of the research currently being done uses advanced assembly techniques, such as precision particle fabrication (PPF), to create microspheres capable of sustained control over drug release.
Sources: en.wikipedia.org
=== Queen's Police Medal (QPM) === England and Wales Anthony Richard Bayliss, Detective Superintendent, Warwickshire Constabulary. Frank Joseph Breen, Detective Constable, Thames Valley Police. Michael Briggs, Commander, Metropolitan Police. Eileen Margaret Eggington, Detective Chief Superintendent, Metropolitan Police. Christopher Fox, Assistant Chief Constable (designated), Warwickshire Constabulary. William Griffiths, Commander, Metropolitan Police. Gareth Jones, lately Detective Superintendent, North Wales Police. David Robertson Kenworthy, Assistant Chief Constable (designated), Avon and Somerset Constabulary. Paul Joseph Scott-Lee, Assistant Chief Constable (designated), Suffolk Constabulary. Roger John Manning, Chief Superintendent, Staffordshire Police. Graham Moore, Assistant Chief Constable (designated), Cambridgeshire Constabulary. Terence Raymond Nicholls, Constable, Metropolitan Police. Robin Edgar Norman Oake, Chief Constable, Isle of Man Constabulary. Peter John Picken, Superintendent (Divisional Commander), West Mercia Constabulary. Colin Potts, Chief Inspector (Divisional Commander), Greater Manchester Police. Gordon Michael Rogers, lately Chief Superintendent, Wiltshire Constabulary. Roger Edward Sandall, Chief Superintendent (Divisional Commander), Norfolk Constabulary. Richard Owen Thomas, Assistant Chief Constable (designated), Gwent Constabulary. Scotland Andrew Gibson Brown, Assistant Chief Constable, Lothian and Borders Police. John Orr, , Chief Constable, Strathclyde Police. William Rae, Chief Constable, Dumfries and Galloway Constabulary.
Regardless of their mechanism, the menstrual disturbances associated with spironolactone can usually be controlled well by concomitant treatment with a birth-control pill, due to the progestin component.
A transaminase converts the oxaloacetate to aspartate for transport back across the membrane and into the intermembrane space. In oxidative phosphorylation, the passage of electrons from NADH and FADH2 through the electron transport chain releases the energy to pump protons out of the mitochondrial matrix and into the intermembrane space. This pumping generates a proton motive force that is the net effect of a pH gradient and an electric potential gradient across the inner mitochondrial membrane. Flow of protons down this potential gradient – that is, from the intermembrane space to the matrix – yields ATP by ATP synthase. Three ATP are produced per turn. Although oxygen consumption appears fundamental for the maintenance of the proton motive force, in the event of oxygen shortage (hypoxia), intracellular acidosis (mediated by enhanced glycolytic rates and ATP hydrolysis), contributes to mitochondrial membrane potential and directly drives ATP synthesis. Most of the ATP synthesized in the mitochondria will be used for cellular processes in the cytosol; thus it must be exported from its site of synthesis in the mitochondrial matrix. ATP outward movement is favored by the inner mitochondrial membrane's electrochemical potential because the cytosol has a relatively positive charge compared to the relatively negative matrix. For every ATP transported out, it costs 1 H+. Producing one ATP costs about 3 H+. Therefore, making and exporting one ATP requires 4H+.
== Special relativity == With the discovery of special relativity by Henri Poincaré and Albert Einstein, the energy was proposed to be a component of an energy-momentum 4-vector. Each of the four components (one of energy and three of momentum) of this vector is separately conserved across time, in any closed system, as seen from any given inertial reference frame. Also conserved is the vector length (Minkowski norm), which is the rest mass for single particles, and the invariant mass for systems of particles (where momenta and energy are separately summed before the length is calculated). The relativistic energy of a single massive particle contains a term related to its rest mass in addition to its kinetic energy of motion. In the limit of zero kinetic energy (or equivalently in the rest frame) of a massive particle, or else in the center of momentum frame for objects or systems which retain kinetic energy, the total energy of a particle or object (including internal kinetic energy in systems) is proportional to the rest mass or invariant mass, as described by the equation
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.